<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097664</url>
  </required_header>
  <id_info>
    <org_study_id>IR.MUI.MED.REC.1400.572</org_study_id>
    <nct_id>NCT05097664</nct_id>
  </id_info>
  <brief_title>Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran</brief_title>
  <official_title>Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ahvaz Jundishapur University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Iran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tabriz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guilan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kermanshah University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Semnan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory&#xD;
      syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging&#xD;
      from mild to life-threatening pneumonia.&#xD;
&#xD;
      Mucormycosis has been suspected to cause significant morbidity in infected people since the&#xD;
      outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care&#xD;
      are more vulnerable, as they have reached an advanced stage of their disease. Investigators&#xD;
      will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in&#xD;
      individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a&#xD;
      cross-sectional descriptive multicenter investigation would be conducted on patients with&#xD;
      biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time&#xD;
      interval between COVID19 and mucormycosis, underlying systemic disorders, clinical&#xD;
      characteristics, disease course, and outcomes would be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will achieved the following data from the participants:&#xD;
&#xD;
        1. Demographic&#xD;
&#xD;
        2. Past medical/habitual history&#xD;
&#xD;
        3. COVID-19 status and related risk factors&#xD;
&#xD;
        4. Mucormycosis status and related risk factors&#xD;
&#xD;
        5. Ocular examination and imaging&#xD;
&#xD;
        6. Follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vision loss</measure>
    <time_frame>3 months</time_frame>
    <description>Prevalence of Vision loss in COVID-19 patients with Mucormycosis co-infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors</measure>
    <time_frame>3 months</time_frame>
    <description>Related risk factors for vision loss</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>COVID-19</condition>
  <condition>Mucormycosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Coronavirus Disease-Associated Mucormycosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed case of Mucormycosis in COVID-19 pandemic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People with acute or severely ill conditions that prevent them from ophthalmic&#xD;
             examination.&#xD;
&#xD;
          -  Patient, or legal representative opposing the pursuit of the research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohsen Pourazizi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan Eye Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohsen Pourazizi, M.D.</last_name>
    <phone>00983134452036</phone>
    <email>m.pourazizi@med.mui.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Isfahan University of Medical Sciences</name>
      <address>
        <city>Isfahan</city>
        <zip>+98</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohsen Pourazizi</last_name>
      <phone>+98</phone>
      <email>m.pourazizi@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mohsen Pourazizi</investigator_full_name>
    <investigator_title>Dr. Mohsen Pourazizi</investigator_title>
  </responsible_party>
  <keyword>Coronavirus Disease-Associated Mucormycosis</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Rhino-orbital-cerebral mucormycosis</keyword>
  <keyword>Mucormycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Mucormycosis</mesh_term>
    <mesh_term>Zygomycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

